The Real-World Outcome of First Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Multicenter Prospective Cohort Study.

ABSTRACT:

Purpose

The addition of immune checkpoint inhibitors to chemotherapy has improved survival outcomes in patients with extensive-stage small cell lung cancer (ES-SCLC). However, their real-world effectiveness remains unknown. Therefore, we investigated the effectiveness of atezolizumab plus chemotherapy in ES-SCLC in actual clinical settings.

Materials and methods

In this multicenter prospective cohort study, patients with ES-SCLC receiving or scheduled to receive atezolizumab in combination with etoposide and carboplatin were enrolled between June 2021 and August 2022. The primary outcomes were progression-free survival (PFS) and the 1-year overall survival (OS) rate.

Results

A total of 100 patients with ES-SCLC were enrolled from seven centers. Median age was 69 years

SUBMITTER: Choi MG 

PROVIDER: S-EPMC11016637 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature